Embryonic Toxicity Risk

Embryonic toxicity risk describes pharmaceutical potential causing developmental harm during early pregnancy. Thalidomide teratogenicity exemplified catastrophic consequences of inadequate embryonic assessment. Retinoids induce neural tube defects and cardiac malformations. Anticonvulsants produce fetal hydantoin syndrome. Pregnancy registries monitor exposed pregnancies identifying adverse patterns.

Risk stratification guides prescribing decisions in women of childbearing age. Contraceptive requirements eliminate pregnancy risk during teratogenic drug use. Reversible contraception balances efficacy against freedom of choice. Regulatory warnings highlight embryonic risks. Alternative therapeutics selected when embryonic safety uncertain.